SC 13G

Names of Reporting Persons

David Campbell, Ph.D.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☐

SEC USE ONLY

Citizenship or Place of Organization

United States

SC 13G 1 d276981dsc13g.htm SC 13G SC 13G

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Janux Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

47103J 105

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 47103J 105		13G		Page 2 of 4 Pages

(1)	The percentage is calculated based on 41,611,510 shares of Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 9, 2021.


CUSIP No. 47103J 105		13G		Page 3 of 4 Pages

Item 1(a).

Name of Issuer:

Janux Therapeutics, Inc., a Delaware corporation

Item 1(b).

Address of Issuer’s Principal Executive Offices:

11099 N. Torrey Pines Road, Suite 290

La Jolla, CA 92037

Item 2(a).

Name of Person Filing:

David Campbell, Ph.D.

Item 2(b).

Address of Principal Business Office or, if none, Residence:

11099 N. Torrey Pines Road, Suite 290

La Jolla, CA 92037

Item 2(c).

Citizenship:

USA

Item 2(d).

Title of Class of Securities:

Common Stock

Item 2(e).

CUSIP Number:

47103J 10 5

Item 3.

Not applicable

Item 4.

Ownership

(a)

Amount Beneficially Owned: 2,276,612 shares of Common Stock

(b)

Percent of Class: 5.5%

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: 2,276,612

(ii)

Shared power to vote or to direct the vote: 0

(iii)

Sole power to dispose or to direct the disposition of: 2,276,612

(iv)

Shared power to dispose or to direct the disposition of: 0

Item

5. Ownership of Five Percent or Less of a Class

Not applicable

Item

6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable

Item

7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable

Item 8.

Identification and Classification of Members of the Group


CUSIP No. 47103J 105		13G		Page 4 of 4 Pages

Not applicable

Item 9. Notice of Dissolution of a Group

Not applicable

Item 10. Certification

Not applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 10, 2022

Date

/s/ David Campbell

Signature

David Campbell, Ph.D.

Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

SEC Form SC 13G filed by Janux Therapeutics Inc.